S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in

Aptevo Therapeutics Stock Forecast, Price & News

-1.31 (-3.87 %)
(As of 01/15/2021 12:00 AM ET)
Today's Range
Now: $32.51
50-Day Range
MA: $39.69
52-Week Range
Now: $32.51
Volume73,344 shs
Average Volume74,050 shs
Market Capitalization$142.39 million
P/E RatioN/A
Dividend YieldN/A
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome. The company's preclinical candidates include ALG.APV-527, a bispecific antibody to target 4-1BB x 5T4; APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Aptevo Therapeutics logo


Overall MarketRank

1.24 out of 5 stars

Medical Sector

670th out of 1,558 stocks

Pharmaceutical Preparations Industry

340th out of 638 stocks

Analyst Opinion: 1.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:APVO



Sales & Book Value

Annual Sales$32.42 million
Book Value$3.66 per share


Net Income$-40,450,000.00


Market Cap$142.39 million
Next Earnings Date3/24/2021 (Estimated)
-1.31 (-3.87 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive APVO News and Ratings via Email

Sign-up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Aptevo Therapeutics (NASDAQ:APVO) Frequently Asked Questions

How has Aptevo Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Aptevo Therapeutics' stock was trading at $0.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, APVO stock has increased by 7,640.5% and is now trading at $32.51.
View which stocks have been most impacted by COVID-19

Is Aptevo Therapeutics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aptevo Therapeutics stock.
View analyst ratings for Aptevo Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Aptevo Therapeutics?

Wall Street analysts have given Aptevo Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aptevo Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Aptevo Therapeutics' next earnings date?

Aptevo Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 24th 2021.
View our earnings forecast for Aptevo Therapeutics

How were Aptevo Therapeutics' earnings last quarter?

Aptevo Therapeutics Inc. (NASDAQ:APVO) posted its quarterly earnings results on Sunday, November, 15th. The biotechnology company reported ($2.15) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($2.05) by $0.10. The biotechnology company had revenue of $1.46 million for the quarter, compared to the consensus estimate of $0.49 million.
View Aptevo Therapeutics' earnings history

What price target have analysts set for APVO?

2 brokerages have issued 12-month price targets for Aptevo Therapeutics' stock. Their forecasts range from $32.00 to $32.00. On average, they anticipate Aptevo Therapeutics' share price to reach $32.00 in the next year. This suggests that the stock has a possible downside of 1.6%.
View analysts' price targets for Aptevo Therapeutics
or view Wall Street analyst' top-rated stocks.

Are investors shorting Aptevo Therapeutics?

Aptevo Therapeutics saw a decline in short interest during the month of December. As of December 31st, there was short interest totaling 165,800 shares, a decline of 40.1% from the December 15th total of 276,700 shares. Based on an average daily volume of 1,730,000 shares, the short-interest ratio is currently 0.1 days. Approximately 4.2% of the company's stock are short sold.
View Aptevo Therapeutics' Short Interest

Who are some of Aptevo Therapeutics' key competitors?

What other stocks do shareholders of Aptevo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Advanced Micro Devices (AMD), Amarin (AMRN), AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Micron Technology (MU), OPKO Health (OPK), AbbVie (ABBV), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and T2 Biosystems (TTOO).

Who are Aptevo Therapeutics' key executives?

Aptevo Therapeutics' management team includes the following people:
  • Mr. Marvin L. White, Pres, CEO & Director (Age 59, Pay $779.77k)
  • Mr. Jeffrey G. Lamothe, Sr. VP, CFO & Treasurer (Age 55, Pay $533.81k)
  • Dr. Jane A. Gross, Sr. VP & Chief Scientific Officer (Age 64, Pay $485.68k)
  • Ms. Stacey Jurchison, Sr. Director of Investor Relations & Corp. Communications
  • Ms. Heather Boussios, Acting Gen. Counsel & Assistant Sec.
  • Ms. Censia Pottorf, VP of HR

What is Aptevo Therapeutics' stock symbol?

Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."

How do I buy shares of Aptevo Therapeutics?

Shares of APVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aptevo Therapeutics' stock price today?

One share of APVO stock can currently be purchased for approximately $32.51.

How big of a company is Aptevo Therapeutics?

Aptevo Therapeutics has a market capitalization of $142.39 million and generates $32.42 million in revenue each year. The biotechnology company earns $-40,450,000.00 in net income (profit) each year or ($15.27) on an earnings per share basis. Aptevo Therapeutics employs 80 workers across the globe.

What is Aptevo Therapeutics' official website?

The official website for Aptevo Therapeutics is www.aptevotherapeutics.com.

How can I contact Aptevo Therapeutics?

Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company can be reached via phone at 206-838-0500 or via email at [email protected]

This page was last updated on 1/17/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.